An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A company called Umbrella Labs announced it’s starting a series of short research summaries and added three experimental compounds — GW-501516, RAD-140, and MK-677 — to its list of things it plans to study in 2025. That’s essentially a publishing and research-planning move: they’re saying they will take a closer look at these substances and share brief reports about them. The announcement is a business and research update, not a clinical trial result or a treatment approval. Those three names are lab compounds often discussed in fitness and research circles. GW-501516 (sometimes called “Cardarine”) is a molecule that was studied for effects on metabolism and endurance. RAD-140 (also called a “SARM” — a selective androgen receptor modulator) is designed to act like testosterone in some tissues and may affect muscle. MK-677 (also called ibutamoren) is a growth hormone secretagogue: it stimulates the body to release growth hormone and a related hormone called IGF-1. None of these are approved medicines for general use; they’ve mostly been investigated in early research or used off-label in research settings. The announcement itself doesn’t report new experimental results. It says Umbrella Labs will produce “research briefs” and include these three substances in its 2025 investigational catalog. That means we should expect summaries of existing studies or small new lab-focused investigations, not large clinical trials in people. The size, methods, and rigor of any upcoming work weren’t specified in the snippet. So we can’t say whether they’ll test these compounds in animals or humans, how many subjects they’ll use, or whether any findings would change medical practice. Why does this matter? These compounds are already talked about by people interested in performance, aging, and body composition. If a company plans to study them and publish concise, accessible summaries, that could help people understand what the evidence actually says — especially for readers who aren’t scientists. It may also influence researchers, clinicians, or hobbyists who follow experimental therapeutics. However, announcements like this mostly signal intent and transparency rather than delivering new proof that a compound is safe or effective. There are important caveats and risks. GW-501516 raised cancer-signal concerns in animal studies and is not approved for human use. RAD-140 and other SARMs have been linked to hormonal side effects and are not approved medicines; their long-term safety is unclear. MK-677 increases growth hormone and may cause fluid retention, insulin resistance, or other effects. Regulatory agencies generally warn against using these substances outside controlled research. Because the Umbrella Labs item is a research plan, it doesn’t change the regulatory status or safety profile of any of these compounds. Bottom line: Umbrella Labs plans to study and publish brief reports on three contentious research compounds in 2025, which could provide clearer summaries of the science, but it’s not new proof that any of them are safe or effective for people.
Source: Yahoo Finance